French national diagnostic and care protocol for Sjögren's disease.

Maladie de Sjögren Management Recommandations Recommendations Sjögren's disease Traitement Treatment

Journal

La Revue de medecine interne
ISSN: 1768-3122
Titre abrégé: Rev Med Interne
Pays: France
ID NLM: 8101383

Informations de publication

Date de publication:
Aug 2023
Historique:
received: 03 07 2023
accepted: 03 07 2023
medline: 15 8 2023
pubmed: 16 7 2023
entrez: 15 7 2023
Statut: ppublish

Résumé

Sjögren's disease (SD), also known as Sjögren's syndrome (SS) or Gougerot-Sjögren's syndrome in France, is a rare systemic autoimmune disease in its primary form and is characterised by tropism for the exocrine glandular epithelia, particularly the salivary and lacrimal glands. The lymphocytic infiltration of these epithelia will clinically translate into a dry syndrome which, associated with fatigue and pain, constitutes the symptom triad of the disease. In about one third of patients, SD is associated with systemic complications that can affect the joints, skin, lungs, kidneys, central or peripheral nervous system, and lymphoid organs with an increased risk of B-cell lymphoma. SD affects women more frequently than men (9/1). The peak frequency is around the age of 50. However, the disease can occur at any age, with paediatric forms occurring even though they remain rare. SD can occur alone or in association with other systemic autoimmune diseases. In its isolated or primary form, the prevalence of SD is estimated to be between 1 per 1000 and 1 per 10,000 inhabitants. The most recent classification criteria were developed in 2016 by EULAR and ACR. The course and prognosis of the disease are highly variable and depend on the presence of systemic involvement and the severity of the dryness of the eyes and mouth. The current approach is therefore to identify at an early stage those patients most at risk of systemic complications or lymphoma, who require close follow-up. On the other hand, regular monitoring of the ophthalmological damage and of the dental status should be ensured to reduce the consequences.

Identifiants

pubmed: 37453854
pii: S0248-8663(23)00679-3
doi: 10.1016/j.revmed.2023.07.001
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

423-457

Informations de copyright

Copyright © 2023. Published by Elsevier Masson SAS.

Auteurs

Valérie Devauchelle-Pensec (V)

Service de Rhumatologie, CHU de Brest, Inserm 1227, LBAI, Université de Bretagne Occidentale, Centre de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), 29609 Brest cedex, France. Electronic address: valerie.devauchelle-pensec@chu-brest.fr.

Xavier Mariette (X)

Service de Rhumatologie, Hôpital Bicètre, AP-HP, Université Paris-Saclay, Paris, France.

Anas-Alexis Benyoussef (AA)

Service d'ophtalmologie, CHU de Brest, Brest, France.

Sylvie Boisrame (S)

UFR d'Odontologie, University of Western Brittany, CHU de Brest, 29200 Brest, France.

Béatrice Cochener (B)

Service d'ophtalmologie, CHU de Brest, Brest, France.

Divi Cornec (D)

Service de Rhumatologie, CHU de Brest, Inserm 1227, LBAI, Université de Bretagne Occidentale, Centre de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), 29609 Brest cedex, France.

Gaëtane Nocturne (G)

Service de Rhumatologie, Hôpital Bicètre, AP-HP, Université Paris-Saclay, Paris, France.

Jacques Eric Gottenberg (JE)

Service de Rhumatologie, Hôpitaux Universitaires de Strasbourg, RESO, Centre de Référence des Maladies Auto-Immunes Systémiques Rares Est Sud-Ouest, 67000 Strasbourg, France.

Eric Hachulla (E)

Service de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Université de Lille, Inserm, CHU Lille, U1286, INFINITE, Institute for Translational Research in Inflammation, Lille, France.

Pierre Labalette (P)

Service d'Ophtalmologie, Hôpital Huriez, CHU de Lille, rue Michel-Polonowski, 59000 Lille, France.

Véronique Le Guern (V)

Department of Internal Medicine, Hôpital Cochin, Paris, France.

Ruth M'Bwang Seppoh (R)

Gynaecology, 29800 Landerneau, France.

Jacques Morel (J)

Département de Rhumatologie, CHU de Montpellier, Hôpital Lapeyronie, Inserm, PhyMedExp, CNRS, Montpellier, France.

Marie Orliaguet (M)

UFR d'Odontologie, University of Western Brittany, CHU de Brest, 29200 Brest, France.

Alain Saraux (A)

Service de Rhumatologie, CHU de Brest, Inserm 1227, LBAI, Université de Bretagne Occidentale, Centre de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), 29609 Brest cedex, France.

Raphaèle Seror (R)

Service de Rhumatologie, Hôpital Bicètre, AP-HP, Université Paris-Saclay, Paris, France.

Nathalie Costedoat-Chalumeau (N)

Department of Internal Medicine, Hôpital Cochin, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH